Their Phase 1 data from ASCO abstract showed that all patients who completed 8 treatment cycles of SNK02 demonstrated stable disease, which is great news. Also, they have a Phase 2 trial planned for their Alzheimer's Disease drug in 2Q 2024. Insiders own 52.88% and Institutions hold 21.39%
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.